ORKA
Oruka Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +5.1% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +25 | 38.87M | $3.69B | +30 | −5 |
| Q1 2026 | 76 | +12 | 25.47M | $1.25B | +17 | −5 |
| Q4 2025 | 63 | +1 | 24.86M | $753.58M | +1 | — |
| Q3 2025 | 15 | +1 | 17.63M | $338.97M | +3 | −2 |
| Q2 2025 | 11 | 0 | 11.37M | $127.46M | +1 | −1 |
| Q1 2025 | 8 | +1 | 1.39M | $14.29M | +2 | −1 |
| Q4 2024 | 7 | +1 | 2.25M | $43.63M | +1 | — |
| Q3 2024 | 5 | +5 | 1.06M | $25.93M | +5 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 5.62M | — | $62.96M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 5.62M | — | $62.96M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Fidelity (FMR) ✦ | 5.62M | — | $62.96M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 1.99M | — | $22.30M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 1.99M | — | $22.30M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 1.99M | — | $22.30M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 1.99M | — | $22.30M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 1.99M | — | $22.30M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 1.99M | — | $22.30M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | The Vanguard Group ✦ (passive) | 1.82M | — | $20.37M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passive) | 1.82M | — | $20.37M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 1.82M | — | $20.37M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passive) | 707.41K | +100.6% | $7.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Geode Capital Management ✦ (passive) | 707.41K | +100.6% | $7.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 410.88K | -0.2% | $4.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 410.88K | -0.2% | $4.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passive) | 372.81K | +330.1% | $4.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 330.00K | -3.6% | $3.70M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 67.64K | New | $758,300 | 0.0% | New | 1 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 32.34K | +48.1% | $362,554 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | Renaissance Technologies ✦ | 13.90K | -61.2% | $155,819 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 22 | Millennium Management ✦ | 12.33K | -77.2% | $138,174 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $758,300 | 0.0% |
Exited
| Wellington Management | $897,761 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 183 holders, 52.32M shares, $2.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 900 sh · $98,687
Officer · 300 sh · $33,155
Officer · 3.32K sh · $371,886
Officer · 2.48K sh · $279,154
Officer · 3.63K sh · $384,963
Officer · 10.43K sh · $1.12M
Officer · 14.70K sh · $1.59M
Officer · 10.20K sh · $1.11M
Officer · 9.19K sh · $1.01M
Officer · 3.85K sh · $427,547
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
19.5% of class · View original SEC filing ↗